Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director · President and CEO | September 08, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date September 08, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 522,968 |
Ending reported balance
After 2026-09-10 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-08 · Exercise / conversion · Acquired 54,174 · Balance 577,142 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Row 2 · 2026-09-08 · Sale · Disposed 54,174 · Balance 522,968 F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 3 · 2026-09-09 · Exercise / conversion · Acquired 63,548 · Balance 586,516 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Row 4 · 2026-09-09 · Sale · Disposed 63,548 · Balance 522,968 F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 5 · 2026-09-10 · Exercise / conversion · Acquired 7,278 · Balance 530,246 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Row 6 · 2026-09-10 · Sale · Disposed 7,278 · Balance 522,968 F4: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.58 · Expires 2026-10-11 | Direct | 70,826 |
Reported balance
After 2026-09-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-08 · Exercise / conversion · Disposed 54,174 · Balance 70,826 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.58 · Expires 2026-10-11 | Direct | 7,278 |
Reported balance
After 2026-09-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-09 · Exercise / conversion · Disposed 63,548 · Balance 7,278 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.58 · Expires 2026-10-11 | Direct | 0 |
Reported balance
After 2026-09-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-10 · Exercise / conversion · Disposed 7,278 · Balance 0 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2021 Filed Feb 26, 2021 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014981 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,144 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 01:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-21-004570 · doc4.xml · derivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,742 Underlying: Common Stock · 13,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested on the last day of each month following the vesting commencement date. The option became fully vested on April 25, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 01:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 24,846 | $24.60 | $611,104.76 |
DisclosureSEC source: 0001209191-21-004570 · doc4.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,144 F1 · kind: The sales reported in this Form 4 include: (a) the open market sale of 13,000 shares of common stock acquired pursuant to the exercise of options to purchase common stock; and (b) the open market sale of an additional 11,846 shares of common stock. Such transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.01 to $24.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 01:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 13,000 | $4.21 | $54,730.00 |
DisclosureSEC source: 0001209191-21-004570 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2020 Filed May 1, 2020 21:32 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-026593 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,990 Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 22:14 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-20-020714 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,087 Underlying: Common Stock · 10,000 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 22:14 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 10,000 | $1.89 | $18,900.00 |
DisclosureSEC source: 0001209191-20-020714 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:04 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 18,344 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-018752 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,344 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became fully vested on September 1, 2019. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:04 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 18,344 | $1.16 | $21,279.04 |
DisclosureSEC source: 0001209191-20-018752 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,822 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2020. Read SEC document |
| February 28, 2020 Filed Feb 28, 2020 22:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 235,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-014097 · doc4.xml · derivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 235,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| December 03, 2019 Filed Dec 3, 2019 23:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | PurchaseCommon Stock | 20,000 | $5.65 | $113,000.00 |
DisclosureSEC source: 0001209191-19-058799 · doc4.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,824 Read SEC document |
| December 03, 2019 Filed Dec 3, 2019 23:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | PurchaseCommon Stock | 10,000 | $5.55 | $55,500.00 |
DisclosureSEC source: 0001209191-19-058799 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,824 Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:58 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-19-058295 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,343 Underlying: Common Stock · 4,000 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:58 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 4,000 | $1.16 | $4,640.00 |
DisclosureSEC source: 0001209191-19-058295 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,032 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2019. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 22:15 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 10,792 | $8.85 | $95,535.10 |
DisclosureSEC source: 0001209191-19-045195 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,792 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.2504, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 1,753 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 8, 2019. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 2,183 | $8.03 | $17,529.49 |
DisclosureSEC source: 0001209191-19-015935 · doc4.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,831 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 172,500 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001209191-19-015935 · doc4.xml · derivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,500 Underlying: Common Stock · 172,500 shares Expires 2029-02-27 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 28,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015935 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,014 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:37 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 10,132 | $7.71 | $78,117.72 |
DisclosureSEC source: 0001209191-19-008690 · doc4.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,264 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:37 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 777 | $8.10 | $6,292.22 |
DisclosureSEC source: 0001209191-19-008690 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,396 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 00:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 22,344 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-19-003606 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,343 Underlying: Common Stock · 22,344 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 00:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 22,344 | $1.16 | $25,919.04 |
DisclosureSEC source: 0001209191-19-003606 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2018 Filed Aug 18, 2018 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 54,700 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001209191-18-047547 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,700 Underlying: Common Stock · 54,700 shares Expires 2028-08-14 F2 · derivative.exercise_date: 1/3rd of the total number of shares underlying this option shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020. Read SEC document |
| August 15, 2018 Filed Aug 18, 2018 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 82,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047547 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,829 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest as follows: 1/3rd of the total number of shares shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020. Read SEC document |
| July 12, 2018 Filed Jul 13, 2018 22:36 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-042575 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,779 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his son. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:50 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 13,516 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-18-029672 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,687 Underlying: Common Stock · 13,516 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:50 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 13,516 | $1.16 | $15,678.56 |
DisclosureSEC source: 0001209191-18-029672 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 21:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-18-023177 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,203 Underlying: Common Stock · 20,000 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 21:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 20,000 | $1.16 | $23,200.00 |
DisclosureSEC source: 0001209191-18-023177 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 21:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 11,298 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-18-021949 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,298 shares Expires 2023-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 21:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 11,298 | $0.87 | $9,829.26 |
DisclosureSEC source: 0001209191-18-021949 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,706 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2018. Read SEC document |
| February 28, 2018 Filed Mar 3, 2018 00:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $16.95 | $0.00 |
DisclosureSEC source: 0001209191-18-016037 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-27 F3 · derivative.exercise_date: The shares underlying this option shall vest as to 25% after one year following the grant date, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| February 28, 2018 Filed Mar 3, 2018 00:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016037 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,259 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date. F2 · balance_after: Includes 2,000 shares and 1,822 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2017 and September 8, 2017, respectively. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 00:54 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 8,210 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-17-066882 · doc4.xml · derivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,087 Underlying: Common Stock · 8,210 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 00:54 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 8,210 | $19.56 | $160,569.54 |
DisclosureSEC source: 0001209191-17-066882 · doc4.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,437 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 9, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.50 to $19.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 00:54 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 8,210 | $1.89 | $15,516.90 |
DisclosureSEC source: 0001209191-17-066882 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 02:28 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 1,790 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-17-066699 · doc4.xml · derivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,297 Underlying: Common Stock · 1,790 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 02:28 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 1,790 | $19.55 | $34,987.34 |
DisclosureSEC source: 0001209191-17-066699 · doc4.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,437 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 9, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.50 to $19.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 02:28 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 1,790 | $1.89 | $3,383.10 |
DisclosureSEC source: 0001209191-17-066699 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2017 Filed May 11, 2017 00:44 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 19,099 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-17-031420 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,203 Underlying: Common Stock · 19,099 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| May 09, 2017 Filed May 11, 2017 00:44 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 19,099 | $1.16 | $22,154.84 |
DisclosureSEC source: 0001209191-17-031420 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2017 Filed Apr 8, 2017 01:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-17-026368 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,302 Underlying: Common Stock · 20,000 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| April 06, 2017 Filed Apr 8, 2017 01:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 20,000 | $1.16 | $23,200.00 |
DisclosureSEC source: 0001209191-17-026368 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 16,362 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-17-020336 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,297 Underlying: Common Stock · 16,362 shares Expires 2023-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 16,362 | $0.87 | $14,234.94 |
DisclosureSEC source: 0001209191-17-020336 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2016 Filed Feb 3, 2017 16:37 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-17-007438 · doc5.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,659 Underlying: Common Stock · 3,000 shares Expires 2023-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option shall vest on the last day of each month following the first anniversary of the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| December 22, 2016 Filed Feb 3, 2017 16:37 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 3,000 | $0.87 | $2,610.00 |
DisclosureSEC source: 0001209191-17-007438 · doc5.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 20:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 320,000 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001209191-16-145810 · doc4.xml · derivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2026-10-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the vesting commencement date of August 10, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.